Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 9:03 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 697–720 of 7,065 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Urological Disease Clear all
Completed Phase 2Phase 3 Interventional

Frequent Hemodialysis Network: Daily Trial

NCT00264758
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
Conventional hemodialysis, Frequent hemodialysis
Device
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
13 Years and older
Enrollment
245 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
2
States / cities
San Francisco, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 3, 2014 · Synced Oct 23, 2026, 9:03 PM EDT
Terminated Not applicable Interventional

Investigating Marrow Infiltrating Lymphocytes in Renal Cell Carcinoma

NCT04341740
View directory record Official record
Conditions
Renal Cell Carcinoma, Urothelial Carcinoma
Interventions
Bone Marrow Aspirate
Procedure
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Dec 13, 2023 · Synced Oct 23, 2026, 9:03 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of Avacopan in Participants With Normal Renal Function and Participants With End-Stage Renal Disease (ESRD)

NCT06468826
View directory record Official record
Conditions
End-Stage Renal Disease (ESRD)
Interventions
Avacopan
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 75 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
2
States / cities
Miami Lakes, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 23, 2026, 9:03 PM EDT
Completed Phase 2 Interventional Results available

Natural Killer Cells Plus IL-2 Following Chemotherapy to Treat Advanced Melanoma or Kidney Cancer

NCT00328861
View directory record Official record
Conditions
Metastatic Melanoma, Metastatic Kidney Cancer
Interventions
Natural Killer (NK) Lymphocytes, IL-2, Cyclophosphamide, Fludarabine
Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 5, 2012 · Synced Oct 23, 2026, 9:03 PM EDT
Completed Phase 2 Interventional Results available

Evaluation the Treatment of Tamoxifen of Low/Intermediate Risk Bladder Tumors

NCT02197897
View directory record Official record
Conditions
Bladder Cancer
Interventions
Tamoxifen Citrate
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
21 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 13, 2021 · Synced Oct 23, 2026, 9:03 PM EDT
Recruiting Phase 2Phase 3 Interventional Accepts healthy volunteers

Amniotic Membrane Therapy for Interstitial Cystitis/Painful Bladder Syndrome

NCT06096597
View directory record Official record
Conditions
Interstitial Cystitis, Painful Bladder Syndrome, Painful Bladder Syndrome (PBS)
Interventions
Clarix Flo, Placebo
Drug
Lead sponsor
David Sheyn
Other
Eligibility
18 Years and older · Female only
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
Clevleand, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Oct 23, 2026, 9:03 PM EDT
Completed Not applicable Interventional

Peer Support In Dialysis

NCT05400720
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
Mentoring
Behavioral
Lead sponsor
Satellite Healthcare
Other
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
2
States / cities
Mountain View, California
Source: ClinicalTrials.gov public record
Updated Sep 21, 2023 · Synced Oct 23, 2026, 9:03 PM EDT
Completed No phase listed Observational

Acute Kidney Injury in Premature Infants

NCT00573079
View directory record Official record
Conditions
Acute Kidney Injury
Interventions
Not listed
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
1 Minute and older
Enrollment
237 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated May 14, 2020 · Synced Oct 23, 2026, 9:03 PM EDT
Terminated Phase 2 Interventional Results available

Gemcitabine Hydrochloride and Cisplatin Before Surgery in Treating Patients With Muscle Invasive Bladder Cancer

NCT01611662
View directory record Official record
Conditions
Distal Urethral Cancer, Proximal Urethral Cancer, Squamous Cell Carcinoma of the Bladder, Stage II Bladder Cancer, Stage III Bladder Cancer, Urethral Cancer Associated With Invasive Bladder Cancer
Interventions
gemcitabine hydrochloride, cisplatin, therapeutic conventional surgery, laboratory biomarker analysis
Drug · Procedure · Other
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
2
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 29, 2019 · Synced Oct 23, 2026, 9:03 PM EDT
Terminated Phase 1 Interventional

Safety and Pharmacokinetics of FG-3019 in Adolescents and Adults With Focal Segmental Glomerulosclerosis (FSGS)

NCT00782561
View directory record Official record
Conditions
Focal Segmental Glomerulosclerosis
Interventions
FG-3019
Drug
Lead sponsor
Kyntra Bio
Industry
Eligibility
12 Years to 64 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
3
States / cities
New Hyde Park, New York • Chapel Hill, North Carolina • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 31, 2019 · Synced Oct 23, 2026, 9:03 PM EDT
Completed Not applicable Interventional

Using Informatics to Enhance Care of Older Emergency Department Patients

NCT00297869
View directory record Official record
Conditions
Elderly; Renal Insufficiency
Interventions
Computer-Assisted Decision Support
Procedure
Lead sponsor
Indiana University
Other
Eligibility
Not listed
Enrollment
1,350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Oct 5, 2016 · Synced Oct 23, 2026, 9:03 PM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Mixed Incontinence: Medical Or Surgical Approach?

NCT00803270
View directory record Official record
Conditions
Urinary Incontinence
Interventions
Non-Surgical Intervention, Surgical
Drug · Procedure
Lead sponsor
Carelon Research
Other
Eligibility
21 Years and older · Female only
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
10
States / cities
Birmingham, Alabama • San Diego, California • Maywood, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated May 10, 2013 · Synced Oct 23, 2026, 9:03 PM EDT
Completed Phase 2 Interventional Results available

Prevention of Acute Kidney Injury in Cardiac Surgery Patients

NCT00921518
View directory record Official record
Conditions
Kidney Injury
Interventions
0.9% Sodium Chloride (Placebo), Sodium Bicarbonate
Drug
Lead sponsor
Community Medical Center, Scranton, PA
Other
Eligibility
18 Years and older
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Scranton, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 15, 2014 · Synced Oct 23, 2026, 9:03 PM EDT
Active, not recruiting No phase listed Observational

Cardiopulmonary Bypass Induced Red Blood Cell Lysis

NCT05189262
View directory record Official record
Conditions
Cardiopulmonary Bypass, Cardiac Surgery, Kidney Injury, Acute
Interventions
Blood and urine collection
Other
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 88 Years
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 23, 2026, 9:03 PM EDT
Completed Not applicable Interventional

Physical Therapy in Women With Interstitial Cystitis

NCT00733603
View directory record Official record
Conditions
Interstitial Cystitis, Painful Bladder Syndrome
Interventions
Global Therapeutic Massages (GTM), Myofascial Tissue Manipulation (MTM)
Other
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years and older · Female only
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
10
States / cities
San Diego, California • Stanford, California • Maywood, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 22, 2021 · Synced Oct 23, 2026, 9:03 PM EDT
Completed Phase 3 Interventional Results available

Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera®) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects

NCT04707768
View directory record Official record
Conditions
Anemia Associated With Chronic Kidney Disease (CKD)
Interventions
Vadadustat, Mircera®
Drug
Lead sponsor
Akebia Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
456 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
58
States / cities
Huntsville, Alabama • Phoenix, Arizona • Pine Bluff, Arkansas + 51 more
Source: ClinicalTrials.gov public record
Updated Jan 15, 2025 · Synced Oct 23, 2026, 9:03 PM EDT
Recruiting Not applicable Interventional

Comparing Two Weight Loss Programs for the Prevention of Kidney Cancer Progression Among Patients With Small Renal Masses on Active Surveillance

NCT07714018
View directory record Official record
Conditions
Renal Cell Carcinoma (RCC)
Interventions
Intermittent Fasting, Continuous Energy Restriction (CER)
Other
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 23, 2026, 9:03 PM EDT
Recruiting Phase 2 Interventional

Phase 2 Study of ADX-038 in Complement-Mediated Kidney Disease

NCT06989359
View directory record Official record
Conditions
IgAN, C3G, Complement-mediated Kidney Disease, IgA Nephropathy (IgAN), IC-MPGN
Interventions
ADX-038 Dose Level 2, ADX-038 Dose Level 1
Drug
Lead sponsor
ADARx Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
11
States / cities
Doral, Florida • Miami, Florida • Pembroke Pines, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 23, 2026, 9:03 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Single-dose Study to Investigate the Pharmacokinetics of Intravenous FEP-TAZ in Patients With Renal Impairment

NCT02709382
View directory record Official record
Conditions
Renal Impairment
Interventions
Cefepime and Tazobactam combination
Drug
Lead sponsor
Wockhardt
Industry
Eligibility
18 Years to 80 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 26, 2016 · Synced Oct 23, 2026, 9:03 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Two-Part Study to Determine: Best Medication Formulation and Food Effect

NCT00427596
View directory record Official record
Conditions
Overactive Bladder
Interventions
Solabegron
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 80 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Oct 7, 2008 · Synced Oct 23, 2026, 9:03 PM EDT
Completed Phase 2 Interventional

Safety and Toxicity Study of Sorafenib in Patients With Kidney Cancer

NCT00445042
View directory record Official record
Conditions
Carcinoma, Renal Cell
Interventions
Sorafenib
Drug
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 17, 2016 · Synced Oct 23, 2026, 9:03 PM EDT
Completed Phase 3 Interventional Results available

Study to Test the Long Term Safety and Efficacy of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder

NCT00688688
View directory record Official record
Conditions
Urinary Bladder, Overactive
Interventions
Mirabegron, Tolterodine, Placebo to Mirabegron, Placebo to Tolterodine
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years and older
Enrollment
2,792 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
106
States / cities
Homewood, Alabama • Huntsville, Alabama • Mobile, Alabama + 96 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2024 · Synced Oct 23, 2026, 9:03 PM EDT
Completed Not applicable Interventional

Use of Mucomyst to Ameliorate Oxidant Stress in Diabetics With Proteinuria

NCT00493727
View directory record Official record
Conditions
Diabetes, Proteinuria
Interventions
N-acetylcysteine(Mucomyst)
Drug
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years to 80 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Dayton, Ohio
Source: ClinicalTrials.gov public record
Updated May 19, 2008 · Synced Oct 23, 2026, 9:03 PM EDT
Not yet recruiting Early Phase 1 Interventional Accepts healthy volunteers

Comparing Alkalinizing Agents Efficacy on Stone Risk in Patients on a Metabolically Controlled Diet

NCT04651088
View directory record Official record
Conditions
Kidney Stone
Interventions
Potassium citrate, Sodium bicarbonate, Litholyte, Crystal Lite, Potassium Bicarbonate
Drug · Dietary Supplement
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 90 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 13, 2026 · Synced Oct 23, 2026, 9:03 PM EDT